Telix Pharmaceuticals LimitedASX: TLX

Telix Completes Enrollment in Phase 3 BiPASS Study

· Issued by Telix Pharmaceuticals Limited via ASX

Filed with ASX ·

On 6ix: 6ix.com/news/telix-completes-enrollment-in-phase-3-bipass-study

Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call

Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Page 1 Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway • The Phase 3 BiPASS ™ study of Illuccix®...

View Attachment

6ix hasn’t read this filing yet.

Telix Pharmaceuticals Limited on 6ix

Story so far

Earlier from Telix Pharmaceuticals

Later from Telix Pharmaceuticals

All Telix Pharmaceuticals news releases